Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Article
|
The Success Story of LDL Cholesterol LoweringCirculation research, 2016-02, Vol.118 (4), p.721-731 [Peer Reviewed Journal]2016 American Heart Association, Inc. ;ISSN: 0009-7330 ;EISSN: 1524-4571 ;DOI: 10.1161/CIRCRESAHA.115.306297 ;PMID: 26892969Full text available |
|
2 |
Material Type: Article
|
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular riskEuropean heart journal, 2020-01, Vol.41 (1), p.111-188 [Peer Reviewed Journal]The European Society of Cardiology and the European Atherosclerosis Association 2019. All rights reserved. For permissions please email: journals.permissions@oup.com. 2019 ;Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 0195-668X ;ISSN: 1522-9645 ;EISSN: 1522-9645 ;DOI: 10.1093/eurheartj/ehz455 ;PMID: 31504418Full text available |
|
3 |
Material Type: Article
|
Cognitive Function in a Randomized Trial of EvolocumabThe New England journal of medicine, 2017-08, Vol.377 (7), p.633-643 [Peer Reviewed Journal]Copyright © 2017 Massachusetts Medical Society. All rights reserved. ;info:eu-repo/semantics/openAccess ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1701131 ;PMID: 28813214Full text available |
|
4 |
Material Type: Article
|
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesThe New England journal of medicine, 2015-11, Vol.373 (22), p.2117-2128 [Peer Reviewed Journal]Copyright © 2015 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1504720 ;PMID: 26378978Full text available |
|
5 |
Material Type: Article
|
Inflammatory and Cholesterol Risk in the FOURIER TrialCirculation (New York, N.Y.), 2018-07, Vol.138 (2), p.131-140 [Peer Reviewed Journal]2018 by the American College of Cardiology Foundation and the American Heart Association, Inc. ;2018 American Heart Association, Inc. ;ISSN: 0009-7322 ;EISSN: 1524-4539 ;DOI: 10.1161/CIRCULATIONAHA.118.034032 ;PMID: 29530884Full text available |
|
6 |
Material Type: Article
|
Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trialsThe Lancet (British edition), 2022-09, Vol.400 (10355), p.832-845 [Peer Reviewed Journal]2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license ;Copyright © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. ;2022. The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. This work is published under https://creativecommons.org/licenses/by/3.0/ (theLicense”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(22)01545-8 ;PMID: 36049498Full text available |
|
7 |
Material Type: Article
|
Atherothrombotic Risk Stratification and Ezetimibe for Secondary PreventionJournal of the American College of Cardiology, 2017-02, Vol.69 (8), p.911-921 [Peer Reviewed Journal]American College of Cardiology Foundation ;2017 American College of Cardiology Foundation ;Copyright © 2017 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. ;Copyright Elsevier Limited Feb 28, 2017 ;ISSN: 0735-1097 ;EISSN: 1558-3597 ;DOI: 10.1016/j.jacc.2016.11.070 ;PMID: 28231942Full text available |
|
8 |
Material Type: Article
|
Evaluation of the effects of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR‐Preserved TrialEuropean journal of heart failure, 2019-10, Vol.21 (10), p.1279-1287 [Peer Reviewed Journal]Attribution - NonCommercial ;ISSN: 1388-9842 ;EISSN: 1879-0844 ;DOI: 10.1002/ejhf.1596 ;PMID: 31523904Digital Resources/Online E-Resources |
|
9 |
Material Type: Article
|
Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER TrialJournal of the American College of Cardiology, 2019-06, Vol.73 (23), p.2961-2970 [Peer Reviewed Journal]Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. ;2019. American College of Cardiology Foundation ;ISSN: 0735-1097 ;ISSN: 1558-3597 ;EISSN: 1558-3597 ;DOI: 10.1016/j.jacc.2019.03.513 ;PMID: 31196453Full text available |
|
10 |
Material Type: Article
|
Evaluation of the effect of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR‐Reduced trialEuropean journal of heart failure, 2019-10, Vol.21 (10), p.1270-1278 [Peer Reviewed Journal]Attribution - NonCommercial ;ISSN: 1388-9842 ;EISSN: 1879-0844 ;DOI: 10.1002/ejhf.1536 ;PMID: 31584231Digital Resources/Online E-Resources |
|
11 |
Material Type: Article
|
Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trialThe American heart journal, 2016-03, Vol.173, p.94-101 [Peer Reviewed Journal]Mosby, Inc. ;2015 Elsevier Inc. ;Copyright © 2015 Elsevier Inc. All rights reserved. ;Copyright Elsevier Limited Mar 1, 2016 ;ISSN: 0002-8703 ;EISSN: 1097-6744 ;DOI: 10.1016/j.ahj.2015.11.015 ;PMID: 26920601Full text available |
|
12 |
Material Type: Article
|
Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trialsThe Lancet (British edition), 2010-02, Vol.375 (9716), p.735-742 [Peer Reviewed Journal]Elsevier Ltd ;2010 Elsevier Ltd ;2015 INIST-CNRS ;Copyright 2010 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Feb 27-Mar 5, 2010 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(09)61965-6 ;PMID: 20167359 ;CODEN: LANCAOFull text available |
|
13 |
Material Type: Article
|
The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous ThromboembolismCirculation (New York, N.Y.), 2020-05, Vol.141 (20), p.1600-1607 [Peer Reviewed Journal]2020 by the American College of Cardiology Foundation and the American Heart Association, Inc. ;ISSN: 0009-7322 ;EISSN: 1524-4539 ;DOI: 10.1161/CIRCULATIONAHA.120.046397 ;PMID: 32223429Full text available |
|
14 |
Material Type: Article
|
The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trialsEuropean heart journal, 2015-06, Vol.36 (24), p.1536-1546 [Peer Reviewed Journal]Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2015. For permissions please email: journals.permissions@oup.com. ;The Author 2015. Published by Oxford University Press on behalf of the European Society of Cardiology. 2015 ;ISSN: 0195-668X ;EISSN: 1522-9645 ;DOI: 10.1093/eurheartj/ehv072 ;PMID: 25802390Full text available |
|
15 |
Material Type: Article
|
Efficacy and Safety of Long-Term Evolocumab Use Among Asian Subjects ― A Subgroup Analysis of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) TrialCirculation Journal, 2021/10/25, Vol.85(11), pp.2063-2070 [Peer Reviewed Journal]2021, THE JAPANESE CIRCULATION SOCIETY ;ISSN: 1346-9843 ;EISSN: 1347-4820 ;DOI: 10.1253/circj.CJ-20-1051 ;PMID: 33980763Full text available |
|
16 |
Material Type: Article
|
Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S)The Lancet (British edition), 2004-08, Vol.364 (9436), p.771-777 [Peer Reviewed Journal]2004 Elsevier Ltd ;2004 INIST-CNRS ;Copyright Lancet Ltd. Aug 28-Sep 3, 2004 ;Copyright Elsevier Limited Aug 28, 2004 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(04)16936-5 ;PMID: 15337403 ;CODEN: LANCAOFull text available |
|
17 |
Material Type: Article
|
High-dose atorvastatin is superior to moderate-dose simvastatin in preventing peripheral arterial diseaseHeart (British Cardiac Society), 2015-03, Vol.101 (5), p.356-362 [Peer Reviewed Journal]Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions. ;Copyright: 2015 Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;ISSN: 1355-6037 ;EISSN: 1468-201X ;DOI: 10.1136/heartjnl-2014-306906 ;PMID: 25595417Full text available |
|
18 |
Material Type: Article
|
Dynamic path analysis - a useful tool to investigate mediation processes in clinical survival trialsStatistics in medicine, 2015-12, Vol.34 (29), p.3866-3887 [Peer Reviewed Journal]Copyright © 2015 John Wiley & Sons, Ltd. ;ISSN: 0277-6715 ;EISSN: 1097-0258 ;DOI: 10.1002/sim.6598 ;PMID: 26278111 ;CODEN: SMEDDAFull text available |
|
19 |
Material Type: Article
|
Sustained Improvement of Arterial Stiffness and Blood Pressure after Long-Term Rosuvastatin Treatment in Patients with Inflammatory Joint Diseases: Results from the RORA-AS StudyPloS one, 2016-04, Vol.11 (4), p.e0153440-e0153440 [Peer Reviewed Journal]COPYRIGHT 2016 Public Library of Science ;COPYRIGHT 2016 Public Library of Science ;2016 Ikdahl et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;info:eu-repo/semantics/openAccess ;2016 Ikdahl et al 2016 Ikdahl et al ;ISSN: 1932-6203 ;EISSN: 1932-6203 ;DOI: 10.1371/journal.pone.0153440 ;PMID: 27093159Full text available |
|
20 |
Material Type: Article
|
Lipoprotein‐Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart DiseaseJournal of the American Heart Association, 2016-06, Vol.5 (6), p.n/a [Peer Reviewed Journal]2016 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell. ;ISSN: 2047-9980 ;EISSN: 2047-9980 ;DOI: 10.1161/JAHA.116.003407 ;PMID: 27329448Full text available |